Digest Réseau Comment ça marche
Réseau
/
Sociétés
Im
Non vérifié

ImmunityBio, Inc.

Ce que nous écrivons

BiotechnologieIndustrie pharmaceutiqueMédecine - DiversOncologieSanté

68 communiqués de presse

Voir tous les communiqués de presse
07/05/2026
Marché financier
Biotechnologie
Santé
Santé Publique
Industrie pharmaceutique
Oncologie
Équipement médical et sanitaire
Science
VIH, SIDA et maladies auto-immunes
Médecine - Divers
ImmunityBio Reports Record Q1 2026 Results: Net Product Revenue Increased Nearly 2.7x Year-Over-Year to $44 Million in Q1 2026 Expanding on the 2025 Full Year 700% Year-Over-Year Revenue Growth; Cash and Marketable Securities Total $381 Million
Source
ImmunityBio, Inc.
Émetteur
Business Wire
1.00
0
05/05/2026
Événements
Expos
Industrie
Oncologie
Santé
Médecine - Divers
Science
Industrie pharmaceutique
Biotechnologie
ImmunityBio to Present New Comparative Data, Scientific Advances in Non-Muscle Invasive Bladder Cancer CIS and an Update on BCG Naïve Registrational Trial at American Urological Association Annual Meeting
Source
ImmunityBio, Inc.
Émetteur
Business Wire
1.00
0
21/04/2026
Marché du travail
Industrie
Biotechnologie
Industrie pharmaceutique
Santé
Oncologie
ImmunityBio Announces ANKTIVA® Is Now Available in Saudi Arabia for Bladder and Lung Cancer Patients; Market Entry Achieved Within Two Months of MENA Partnership
Source
ImmunityBio, Inc.
Émetteur
Business Wire
1.00
0
09/04/2026
Marché financier
Industrie
Biotechnologie
Industrie pharmaceutique
Santé
Oncologie
ImmunityBio Reports Net Product Revenue Increased Nearly 2.7 Times Year-Over-Year to Record $44 Million in Q1 2026 and $381 Million in Cash and Marketable Securities
Source
ImmunityBio, Inc.
Émetteur
Business Wire
1.00
0
06/04/2026
Oncologie
Publicité
Santé
Communication
Hygiène alimentaire
Industrie pharmaceutique
Biotechnologie
ImmunityBio Addresses FDA Correspondence and Reaffirms Commitment to Advertising Compliance
Source
ImmunityBio, Inc.
Émetteur
Business Wire
1.00
0
31/03/2026
Industrie
Biotechnologie
Industrie pharmaceutique
Santé
ImmunityBio Strengthens Balance Sheet with $100 Million of Financing Transactions Including $75 Million of Non-Dilutive Financing to Support Global Expansion and Advancement of Broader Immunotherapy Pipeline
Source
ImmunityBio, Inc.
Émetteur
Business Wire
1.00
0
26/03/2026
Industrie
Biotechnologie
Santé
Industrie pharmaceutique
Médecine - Divers
Oncologie
ImmunityBio Confirms Statistical Power in Pivotal Randomized BCG-Naïve NMIBC Trial to Detect Clinically Meaningful Differences Between ANKTIVA® Plus BCG Versus BCG Alone; Supplemental BLA Submission on Track for 2026
Source
ImmunityBio, Inc.
Émetteur
Business Wire
1.00
0
20/03/2026
Biotechnologie
Santé
Industrie pharmaceutique
Médecine - Divers
Oncologie
Industrie
ImmunityBio Announces Approval in Macau SAR, China for ANKTIVA® in BCG-Unresponsive NMIBC with CIS ± Papillary Tumors
Source
ImmunityBio, Inc.
Émetteur
Business Wire
1.00
0
17/03/2026
Oncologie
Hygiène alimentaire
Santé
Médecine - Divers
Industrie pharmaceutique
Biotechnologie
Industrie
ImmunityBio Announces NCCN® Clinical Practice Guidelines in Oncology Have Been Updated to Include ANKTIVA® Plus BCG for Patients With BCG-Unresponsive NMIBC With Papillary-Only Disease
Source
ImmunityBio, Inc.
Émetteur
Business Wire
1.00
0
13/03/2026
Industrie
Biotechnologie
Santé
Industrie pharmaceutique
Médecine - Divers
Oncologie
ImmunityBio Achieves Milestone with Large-Scale NK Cell Production and Cryopreservation from Over 60 Healthy and Cancer Donors
Source
ImmunityBio, Inc.
Émetteur
Business Wire
1.00
0

Détails du contact

Réseaux sociaux

Followers
0
Compatibilité
0